Headquartered in New Haven, Connecticut, Melinta Therapeutics, formerly known as Rib-X Pharmaceuticals, is a biopharmaceutical company developing new antibiotics to provide superior coverage, safety and convenience for the treatment of serious and life-threatening infections. The company's proprietary drug discovery platform, which is based on Nobel prize-winning science, provides an atomic-level, three-dimensional understanding of interactions between drug candidates and their bacterial targets and enables Rib X to systematically engineer antibiotics with enhanced characteristics. The company's most advanced product candidate, Delafloxacin, successfully completed a Phase IIb clinical study in acute bacterial skin and skin structure infections in December 2011. Melinta's second product candidate, Radezolid, is currently in Phase II development and is designed to be a potent antibiotic with a safety profile permitting long-term treatment of resistant infections. Melinta is also pursuing development of RX-04, its preclinical program partnered with Sanofi, which has produced new classes of antibiotics designed to combat the most difficult-to-treat, multidrug resistant bacteria.
Warburg Pincus led Melinta’s Series B financing in 2003, Series C financing in 2006 as well as a subsequent financings in 2008 through 2011 to fund the development of its novel antibiotic candidates. In 2012, existing investors, including Warburg Pincus, were joined by new investor Vatera Healthcare Partners in a follow-on financing to fund Phase III development of Delafloxacin.
Back to Previous Page